Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 May 24;61(6):e00427-17.
doi: 10.1128/AAC.00427-17. Print 2017 Jun.

Reply to Anthony et al., "Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment"

M O Fofana  1 , D W Dowdy  2
Affiliations
Comment

Reply to Anthony et al., "Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment"

M O Fofana et al. Antimicrob Agents Chemother. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Anthony RM, Cynamon M, Hoffner S, den Hertog AL, van Soolingen D. 2017. Protecting pyrazinamide, a priority for improving outcomes in multidrug-resistant tuberculosis treatment. Antimicrob Agents Chemother 61:e00258–. doi:10.1128/AAC.00258-17. - DOI - PMC - PubMed
    1. Fofana MO, Shrestha S, Knight GM, Cohen T, White RG, Cobelens F, Dowdy DW. 2017. A multistrain mathematical model to investigate the role of pyrazinamide in the emergence of extensively drug-resistant tuberculosis. Antimicrob Agents Chemother 61:e00498–. doi:10.1128/AAC.00498-16. - DOI - PMC - PubMed
    1. Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Husain A, Hussain A, Ismail N, Kamal M, Mansjö M, Mvusi L, Niemann S, Omar SV, Qadeer E, Rigouts L, Ruesch-Gerdes S, Schito M, Seyfaddinova M, Skrahina A, Tahseen S, Wells WA, Mukadi YD, Kimerling M, Floyd K, Weyer K, Raviglione MC. 2016. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis 16:1185–1192. doi:10.1016/S1473-3099(16)30190-6. - DOI - PMC - PubMed
    1. Kendall EA, Cohen T, Mitnick CD, Dowdy DW. 2017. Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. Int J Infect Dis 56:185–189. doi:10.1016/j.ijid.2016.12.010. - DOI - PMC - PubMed

LinkOut - more resources